Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.


(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...


(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...


Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...


IN BRIEF: Angle raises GBP20.0 million to fund FDA approval drive


IN BRIEF: Angle to raise GBP20 million through shares placing


UK shareholder meetings calendar - next 7 days


TRADING UPDATES: DP Poland sales improve; Braveheart swings to profit


IN BRIEF: Angle responds to additional information request from US FDA


TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets


TRADING UPDATES: Gamma tips 2021 revenue jump; Smart Metering progress


IN BRIEF: Angle's Parsortix system gets Italian research boost